HDAC Inhibitors and Their Role in Treating Anaplastic Thyroid Carcinoma

In their bid to find the best combination of therapies to treat anaplastic thyroid cancer, John A. Copland III, Ph.D., and a team of researchers at Mayo Clinic's campus in Florida demonstrated that all histone deacetylase (HDAC) inhibitors are not created equal.

Dr. Copland discusses the trial of the PPAR-gamma agonist efatutazone combined with paclitaxel, plus newer findings with HDAC inhibitors combined with paclitaxel — a combination therapy not yet in trial.

For more information

Related Videos